THOUSANDS of women suffering advanced breast cancer can access two new drugs on the NHS.
Charities said the approvals were a “momentous milestone” for patients living with incurable tumours.
Trials show those given Trodelvy, also known as sacituzumab govitecan, lived almost six months longer.
Both drugs have been proven to give women precious extra months.
Trials show those given Trodelvy, also known as sacituzumab govitecan, lived almost six months longer.
It works by slowing tumour growth in those with triple-negative breast cancer and could benefit 650 women a year.
The National Institute for Health and Care Excellence has also approved alpelisib for routine use on the NHS.
Also known as Piqray, trials have shown it can give patients an extra eight months. Around 2,800 women a year could be offered the drug.
New Health Secretary Steve Barclay said the drugs offered patients “more precious moments with loved ones”.
Baroness Delyth Morgan, chief exec of Breast Cancer Now, hailed the “landmark decision” on the approvals as “absolutely fantastic news”.
